SCHEMBL2594655

SCHEMBL2594655

Cc1nn(C(C)C)c2cc(-c3cnc4[nH]ccc4c3)cc(C(=O)O)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 5/20 0.48
PIK3CG P48736 4/20 0.48
KDR P35968 3/20 0.48
PIK3CD O00329 3/20 0.48
PIK3CB P42338 3/20 0.48
ABL1 P00519 2/20 0.48
EGFR P00533 2/20 0.48
HCK P08631 2/20 0.48
SRC P12931 2/20 0.48
MTOR P42345 2/20 0.48
EPHB4 P54760 2/20 0.48
PRKDC P78527 2/20 0.48
MAP4K1 Q92918 1/20 0.44
CDK8 P49336 7/20 0.43
CDK7 P50613 2/20 0.43
PLK4 O00444 1/20 0.43
DCLK1 O15075 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2592542 0.90 CDK8 (0.50) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2592470 0.82 MAP4K1 (0.45) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2594319 0.78 EZH2 (0.59)
SCHEMBL2588507 0.76 MTOR (0.38) PIK3CAMTORROCK2ROCK1LRRK2
SCHEMBL2595663 0.75 RIPK1 (0.51) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2594202 0.75 KDM4E (0.41) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2592103 0.74 CDK8 (0.52) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2592084 0.69 KDM4E (0.41)
SCHEMBL18766941 0.69 ITK (0.61) PIK3CAPIK3CGKDRPIK3CDPIK3CB
SCHEMBL2592086 0.68 ROCK2 (0.40) PIK3CAMTORROCK2ROCK1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
US-9018382-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2015-04-28 US disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
EP-2566328-B1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2015-03-04 EP disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-20140350013-A1 INDAZOLES GLAXOSMITHKLINE LLC 2014-11-27 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
US-8846935-B2 Indazoles GLAXOSMITHKLINE LLC (US) 2014-09-30 US disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 WO disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 US disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B PIK3CA 1051/4885PIK3CG 2027/4885KDR 4139/4885
US-20140350013-A1 INDAZOLES IDH3A, CYP3A7, IDH3B PIK3CA 1051/4885PIK3CG 2027/4885KDR 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.